Ongoing phase I and II trials are using lenvatinib combination therapy with pembrolizumab in the perioperative treatment (NCT04875585), pembrolizumab plus pemetrexed plus carboplatin following treatment with epidermal growth factor receptor-tyrosine kinase inhibitors in epidermal growth factor receptor mutation-positive patients with NSCLC (NCT05258279), GI-101, a bispecific fusion protein of CD80 and interleukin (IL)-2 mutants (NCT04977453), IBI318, a bispecific antibody of PD-1 and PD-L1 (NCT04777084), and envafolimab, a subcutaneous anti-PD-1 antibody formulation (NCT05024214). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.